Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13


An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study).

Coombes RC, Tat T, Miller ML, Reise JA, Mansi JL, Hadjiminas DJ, Shousha S, Elsheikh SE, Lam EW, Horimoto Y, El-Bahrawy M, Aboagye EO, Contractor KB, Shaw JA, Walker RA, Marconell MH, Palmieri C, Stebbing J.

Ann Oncol. 2013 Apr;24(4):924-30. doi: 10.1093/annonc/mds594. Epub 2012 Dec 11.


Evaluation of limited blood sampling population input approaches for kinetic quantification of [18F]fluorothymidine PET data.

Contractor KB, Kenny LM, Coombes CR, Turkheimer FE, Aboagye EO, Rosso L.

EJNMMI Res. 2012 Mar 24;2:11. doi: 10.1186/2191-219X-2-11.


[18F]-3'Deoxy-3'-fluorothymidine positron emission tomography and breast cancer response to docetaxel.

Contractor KB, Kenny LM, Stebbing J, Rosso L, Ahmad R, Jacob J, Challapalli A, Turkheimer F, Al-Nahhas A, Sharma R, Coombes RC, Aboagye EO.

Clin Cancer Res. 2011 Dec 15;17(24):7664-72. doi: 10.1158/1078-0432.CCR-11-0783. Epub 2011 Oct 25.


Biological basis of [¹¹C]choline-positron emission tomography in patients with breast cancer: comparison with [¹⁸F]fluorothymidine positron emission tomography.

Contractor KB, Kenny LM, Stebbing J, Challapalli A, Al-Nahhas A, Palmieri C, Shousha S, Lewis JS, Hogben K, De Nguyen Q, Coombes RC, Aboagye EO.

Nucl Med Commun. 2011 Nov;32(11):997-1004. doi: 10.1097/MNM.0b013e328349567b.


Reproducibility of [11C]choline-positron emission tomography and effect of trastuzumab.

Kenny LM, Contractor KB, Hinz R, Stebbing J, Palmieri C, Jiang J, Shousha S, Al-Nahhas A, Coombes RC, Aboagye EO.

Clin Cancer Res. 2010 Aug 15;16(16):4236-45. doi: 10.1158/1078-0432.CCR-10-0468. Epub 2010 Aug 3.


Kinetic filtering of [(18)F]Fluorothymidine in positron emission tomography studies.

Gray KR, Contractor KB, Kenny LM, Al-Nahhas A, Shousha S, Stebbing J, Wasan HS, Coombes RC, Aboagye EO, Turkheimer FE, Rosso L.

Phys Med Biol. 2010 Feb 7;55(3):695-709. doi: 10.1088/0031-9155/55/3/010. Epub 2010 Jan 13.


Altered tissue 3'-deoxy-3'-[18F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography.

Kenny LM, Contractor KB, Stebbing J, Al-Nahhas A, Palmieri C, Shousha S, Coombes RC, Aboagye EO.

Clin Cancer Res. 2009 Nov 1;15(21):6649-57. doi: 10.1158/1078-0432.CCR-09-1213. Epub 2009 Oct 27.


[11C]choline positron emission tomography in estrogen receptor-positive breast cancer.

Contractor KB, Kenny LM, Stebbing J, Al-Nahhas A, Palmieri C, Sinnett D, Lewis JS, Hogben K, Osman S, Shousha S, Lowdell C, Coombes RC, Aboagye EO.

Clin Cancer Res. 2009 Sep 1;15(17):5503-10. doi: 10.1158/1078-0432.CCR-09-0666. Epub 2009 Aug 25.


Monitoring predominantly cytostatic treatment response with 18F-FDG PET.

Contractor KB, Aboagye EO.

J Nucl Med. 2009 May;50 Suppl 1:97S-105S. doi: 10.2967/jnumed.108.057273. Review.


Peritoneal disease in breast cancer: a specific entity with an extremely poor prognosis.

Tuthill M, Pell R, Guiliani R, Lim A, Gudi M, Contractor KB, Lewis JS, Coombes RC, Stebbing J.

Eur J Cancer. 2009 Aug;45(12):2146-9. doi: 10.1016/j.ejca.2009.04.027. Epub 2009 May 20.


Male breast cancer: is the scenario changing.

Contractor KB, Kaur K, Rodrigues GS, Kulkarni DM, Singhal H.

World J Surg Oncol. 2008 Jun 16;6:58. doi: 10.1186/1477-7819-6-58. Review.


Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients.

Kenny LM, Coombes RC, Oulie I, Contractor KB, Miller M, Spinks TJ, McParland B, Cohen PS, Hui AM, Palmieri C, Osman S, Glaser M, Turton D, Al-Nahhas A, Aboagye EO.

J Nucl Med. 2008 Jun;49(6):879-86. doi: 10.2967/jnumed.107.049452. Epub 2008 May 15.


Major colorectal cancer resection should not be denied to the elderly.

Smith JJ, Lee J, Burke C, Contractor KB, Dawson PM.

Eur J Surg Oncol. 2002 Sep;28(6):661-6.


Supplemental Content

Loading ...
Support Center